Engineered vesicles facilitate the programmed transdermal-intestinal delivery of cinnabar for insomnia mitigation by modulating serotonin-Htr1d-cAMP
Source abstract
Abstract
Insomnia is a prevalent sleep disorder and it affects brain development, with pediatric populations being particularly vulnerable. Cinnabar, a mineral drug composed of HgS, has demonstrated efficacy in alleviating insomnia through suppressing the overactivity of glutamate receptors (NMDA/AMPA), etc. However, oral administration of cinnabar poses risks, including binding with hemoglobin and accumulation in tissues and organs, resulting in neurotoxicity. To overcome these limitations, we developed a novel transdermal and intestinal targeting programmed nanoplatform for cinnabar delivery (TAT/CSK-cinnabar vesicle, TCCV), of which, cinnabar was encapsulated within a lipid vesicle, which was then co-engineered with cell-penetrating peptide TAT and the intestinal-targeting CSK ligand. Accordingly, TCCV showed exceptional sequential penetration through the stratum corneum (SC) and intestinal barriers, and also actively targeted intestinal goblet cells with a 15-fold increase in efficiency compared to non-engineered vesicles. Furthermore, TCCV forms a reservoir releasing cinnabar at the intestinal site with controlled manner, significantly reducing fluctuations in cinnabar concentration in blood and organs, thereby reducing toxicity. In current anti-insomnia studies, TCCV exhibited predominantly enhanced therapeutic efficiency compared to the oral control group, with drug efficiency increased by 1.5 to 2.5-fold. With the analysis of RNA sequencing and 16S rRNA, the regulation of the serotonin (5-HT) production in gut microbes and activating the Htr1d-cAMP pathway of cerebral cortex through the "brain-gut axis" by TCCV is identified as the novel mechanism for the insomnia mitigation effect of cinnabar. This study offers a novel non-invasive transdermal and targeted nanoplatform that significantly improves the efficacy and biosafety of cinnabar delivery and highlights a new gut-brain axis-mediated mechanism in insomnia mitigation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Sleep and related disorders · Sleep and Wakefulness Research · Child Nutrition and Feeding Issues
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (94)
Show source-provided references
1. Subtyping insomnia disorder10.1016/S2215-0366(19)30098-7 ↗
2. Use of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendation
3. Associations between traditional Chinese medicine constitution and depression/anxiety/sleep disturbances in patients with chronic pain: A cross-sectional study
4. Mindfulness-based stress reduction compared with cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: a randomized, partially blinded, noninferiority trial10.1200/JCO.2012.47.7265 ↗
5. Comparative behavioural effects of benzodiazepine and non-benzodiazepine anxiolytics in rhesus monkeys10.1006/phrs.1998.0455 ↗
6. A benzodiazepine used in the treatment of insomnia phase-shifts the mammalian circadian clock10.1038/321167a0 ↗
7. Intrathecal administration of nanoclusters for protecting neurons against oxidative stress in cerebral ischemia/reperfusion injury10.1021/acsnano.9b06780 ↗
8. The anxiolytic effect of cinnabar involves changes of serotonin levels10.1016/j.ejphar.2007.03.018 ↗
9. A review of cinnabar (HgS) and/or realgar (As4S4)-containing traditional medicines10.1016/j.jep.2017.08.037 ↗
10. Mercury in traditional medicines: is cinnabar toxicologically similar to common mercurials?10.3181/0712-MR-336 ↗
11. Elevated peripheral glutamate and upregulated expression of NMDA receptor NR1 subunit in insomnia disorder
12. Model-dependent attenuation of seizures by cinnabar
13. New insights and rethinking of cinnabar for chemical and its pharmacological dynamics10.1080/21655979.2019.1652491 ↗
14. Attenuation by methyl mercury and mercuric sulfide of pentobarbital induced hypnotic tolerance in mice through inhibition of ATPase activities and nitric oxide production in cerebral cortex10.1007/s00204-007-0255-9 ↗
15. Different proteomic profiles of cinnabar upon therapeutic and toxic exposure reveal distinctive biological manifestations10.1016/j.jep.2020.112668 ↗
16. Antidepressant effects and mechanisms of Wuhua herbal tea in a rat model of chronic unpredictable mild stress
17. 0030 insomnia is associated with lower serum antioxidants in the hispanic community health study/study of latinos10.1093/sleep/zsad077.0030 ↗
18. Hepatorenal protective effects of medicinal herbs in An-Gong-Niu-Huang Wan (AGNH) against cinnabar- and realgar-induced oxidative stress and inflammatory damage in mice10.1016/j.fct.2017.11.054 ↗
19. Evaluating the role of re-adsorption of dissolved Hg2+ during cinnabar dissolution using isotope tracer technique10.1016/j.jhazmat.2016.05.084 ↗
20. Hgs deficiency caused restrictive cardiomyopathy via disrupting proteostasis10.7150/ijbs.69024 ↗
21. Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis10.1016/j.apsb.2023.05.025 ↗
22. A transdermal drug delivery system based on nucleic acid nanomaterials for skin photodamage treatment10.1002/adfm.202303580 ↗
23. Self-powered, on-demand transdermal drug delivery system driven by triboelectric nanogenerator10.1016/j.nanoen.2019.05.056 ↗
24. Avoiding a sticky situation: bypassing the mucus barrier for improved local drug delivery10.1016/j.molmed.2020.12.001 ↗
25. Development of novel therapeutics targeting the blood–brain barrier: from barrier to carrier10.1002/advs.202101090 ↗
26. Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL-programmed therapy against melanoma10.1126/sciadv.aba2735 ↗
27. Transdermal siRNA delivery by pH-switchable micelles with targeting effect suppress skin melanoma progression10.1016/j.jconrel.2020.03.023 ↗
28. Nanoscale systems for local drug delivery10.1016/j.nantod.2019.100765 ↗
29. Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo/thermotherapy delivery system for local treatment of colon cancer10.1016/j.biomaterials.2019.01.019 ↗
30. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial10.1038/s41591-022-01936-7 ↗
31. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport10.1016/j.biomaterials.2011.10.075 ↗
32. Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing10.1146/annurev-immunol-051116-052424 ↗
33. An injectable composite co‐assembled dehydropeptide‐based magnetic/plasmonic lipogel for multimodal cancer therapy10.1002/adfm.202402926 ↗
34. Sustainable nanosheet antioxidants for sepsis therapy via scavenging intracellular reactive oxygen and nitrogen species10.1021/acsnano.0c03807 ↗
35. Bacteria-like mesoporous silica-coated gold nanorods for positron emission tomography and photoacoustic imaging-guided chemo-photothermal combined therapy10.1016/j.biomaterials.2018.02.043 ↗
36. N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer10.1016/j.jconrel.2018.03.013 ↗
37. Light-controlled small extracellular vesicle-based spherical nucleic acid nanomotor for enhanced transdermal delivery against skin aging
38. X-rays reveal the internal structure of keratin bundles in whole cells10.1021/acsnano.5b07871 ↗
39. Mouse intestinal goblet cells expressing SV40 T antigen directed by the MUC2 mucin gene promoter undergo apoptosis upon migration to the villi
40. N-trimethyl chitosan coated targeting nanoparticles improve the oral bioavailability and antioxidant activity of vitexin10.1016/j.carbpol.2022.119273 ↗
41. Anti-diabetic effects and mechanisms of action of a Chinese herbal medicine preparation JQ-R in vitro and in diabetic KKAy mice10.1016/j.apsb.2017.04.010 ↗
42. Proteomic analysis of meningiomas reveals clinically distinct molecular patterns10.1093/neuonc/noz084 ↗
43. Sleep deprivation impairs molecular clearance from the human brain10.1093/brain/awaa443 ↗
44. Individual differences in trait anxiety predict the response of the basolateral amygdala to unconsciously processed fearful faces10.1016/j.neuron.2004.12.006 ↗
45. Seizure likelihood varies with day-to-day variations in sleep duration in patients with refractory focal epilepsy: a longitudinal electroencephalography investigation10.1016/j.eclinm.2021.100934 ↗
46. Influence of estradiol, stress, and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats10.1016/S0006-3223(03)00236-1 ↗
47. KDM3A controls postnatal hippocampal neurogenesis via dual regulation of the Wnt/β-catenin signaling pathway
48. Insulin-like growth factor I mitigates post-traumatic stress by inhibiting AMP-kinase in orexin neurons10.1038/s41380-022-01442-9 ↗
49. Neurofilaments as biomarkers in neurological disorders10.1038/s41582-018-0058-z ↗
50. Is β-APP a marker of axonal damage in short-surviving head injury?10.1007/s004010050568 ↗
51. Sleep deprivation and memory: meta-analytic reviews of studies on sleep deprivation before and after learning10.1037/bul0000348 ↗
52. Telephone-guided sleep restriction for insomnia: a randomized sleep diary-controlled trial10.1159/000545138 ↗
53. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders10.1016/j.tins.2004.08.001 ↗
54. Structure and molecular mechanism of signaling for the glucagon-like peptide-1 receptor bound to Gs protein and exendin-P5 biased agonist10.1021/jacs.3c05996 ↗
55. Untangling neurodegeneration10.1038/s41583-022-00629-x ↗
56. The neuroactive potential of the human gut microbiota in quality of life and depression10.1038/s41564-018-0337-x ↗
57. Effects of single and combined low concentrations of neuroactive drugs on Daphnia magna reproduction and transcriptomic responses10.1021/acs.est.9b03228 ↗
58. Gut microbiota modulates the inflammatory response and cognitive impairment induced by sleep deprivation10.1038/s41380-021-01113-1 ↗
59. Akkermansia muciniphila supplementation prevents cognitive impairment in sleep-deprived mice by modulating microglial engulfment of synapses10.1080/19490976.2023.2252764 ↗
60. Differential regulation of β-catenin-mediated transcription via N-and C-terminal co-factors governs identity of murine intestinal epithelial stem cells10.1038/s41467-021-21591-9 ↗
61. A feedback loop between Paxillin and Yorkie sustains Drosophila intestinal homeostasis and regeneration10.1038/s41467-024-55255-1 ↗
62. Transformation, absorption and toxicological mechanisms of silver nanoparticles in the gastrointestinal tract following oral exposure
63. Ultrasonic effects on the degradation kinetics, structural characteristics and protective effects on hepatocyte lipotoxicity induced by palmitic acid of Pueraria Lobata polysaccharides10.1016/j.ultsonch.2023.106652 ↗
64. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta‐analysis10.1111/bjd.14768 ↗
65. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease10.1016/j.cgh.2013.02.015 ↗
66. Gut colonization by Proteobacteria alters host metabolism and modulates cocaine neurobehavioral responses10.1016/j.chom.2022.09.014 ↗
67. A liposome-based adjuvant containing two delivery systems with the ability to induce mucosal immunoglobulin a following a parenteral immunization
68. Targeted delivery of persulfides to the gut: effects on the microbiome10.1002/anie.202014052 ↗
69. Gut mucosal and adipose tissues as health targets of the immunomodulatory mechanisms of probiotics10.1016/j.tifs.2021.04.040 ↗
70. Size and dose dependent effects of silver nanoparticle exposure on intestinal permeability in an in vitro model of the human gut epithelium10.1186/s12951-016-0214-9 ↗
71. In vitro evaluation of dietary compounds to reduce mercury bioavailability10.1016/j.foodchem.2017.12.012 ↗
72. Artificial octopus-limb-like adhesive patches for cupping-driven transdermal delivery with nanoscale control of stratum corneum
73. Multifunctional magnesium organic framework-based microneedle patch for accelerating diabetic wound healing10.1021/acsnano.1c06036 ↗
74. Integration of antimicrobial peptides with gold nanoparticles as unique non-viral vectors for gene delivery to mesenchymal stem cells with antibacterial activity10.1016/j.biomaterials.2016.06.057 ↗
75. Overcoming the reticuloendothelial system barrier to drug delivery with a “don’t-eat-us” strategy10.1021/acsnano.9b05679 ↗
76. ACE2 mediates tryptophan alleviation on diarrhea by repairing intestine barrier involved mTOR pathway10.1186/s11658-024-00603-8 ↗
77. Antibody peptides as cancer vaccine—turning weapons to targets10.1158/1078-0432.CCR-20-3977 ↗
78. The choice of targets and ligands for site-specific delivery of nanomedicine to atherosclerosis10.1093/cvr/cvaa047 ↗
79. Targeted drug delivery systems for atherosclerosis10.1186/s12951-025-03384-0 ↗
80. Main active components of Si-Miao-Yong-An decoction (SMYAD) attenuate autophagy and apoptosis via the PDE5A-AKT and TLR4-NOX4 pathways in isoproterenol (ISO)-induced heart failure models10.1016/j.phrs.2022.106077 ↗
81. Jiawei Xiaoyao San in treatment of anxiety disorder and anxiety: A review
82. Histamine, mast cells, and the enteric nervous system in the irritable bowel syndrome, enteritis, and food allergies10.1136/gut.2005.079046 ↗
83. The microbiota-gut-brain axis: from motility to mood10.1053/j.gastro.2020.10.066 ↗
84. Potential efficacy and mechanism of eight mild-natured and bitter-flavored TCMs based on gut microbiota: A review
85. Pectic polysaccharides: targeting gut microbiota in obesity and intestinal health10.1016/j.carbpol.2022.119363 ↗
86. Gut microbiota in intestinal and liver disease10.1146/annurev-pathol-030320-095722 ↗
87. The use of hydrogel microspheres as cell and drug delivery carriers for bone, cartilage, and soft tissue regeneration
88. Meng · 2025 · vol. 1 · 2
89. Bai · 2025 · OR · 1
90. The gut microbiome and metabolic syndrome10.1172/JCI129194 ↗
91. Transplantation of gut microbiota from old mice into young healthy mice reduces lean mass but not bone mass10.1080/19490976.2023.2236755 ↗
92. Mechanically conditioned cell sheets cultured on thermo-responsive surfaces promote bone regeneration
93. Dysregulated brain-gut axis in the setting of traumatic brain injury: review of mechanisms and anti-inflammatory pharmacotherapies10.1186/s12974-024-03118-3 ↗
94. Advances in natural polysaccharides in Alzheimer's disease and Parkinson's disease: insights from the brain-gut axis10.1016/j.tifs.2024.104678 ↗